Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it.
A consensus meeting was held in Stockholm on Oct. 9, 1993, after consultations with the Swedish Association of Gastroenterology and Gastrointestinal Endoscopy. The meeting was attended by 35 physicians with a special interest in Helicobacter pylori-associated diseases representing the following medical disciplines: gastroenterology, surgery, internal medicine, histopathology, microbiology, immunology, infectious diseases, clinical physiology, and cancer epidemiology. The aims of the meeting were to define and recommend methods of diagnosis, indications for anti-H. pylori therapy, alternatives for treatment regimens, principles of follow-up observation, and suitable measures of quality control. The participants agreed to recommend anti-H. pylori therapy only for the treatment of H. pylori-associated gastric and duodenal ulcer disease. A combination of amoxicillin, 1,000 mg b.i.d., plus omeprazole, 20 mg b.i.d. for 2 weeks was considered the first-line treatment. Second-line options are not specified, but amoxicillin plus a higher-dose omeprazole, clarithromycin plus omeprazole, or various triple regimens were discussed.
Gad
A
A
Unge
P
P
D006801:Humans; D000658:Amoxicillin / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016481:Helicobacter Infections / Q000188:drug therapy; D016480:Helicobacter pylori / Q000302:isolation & purification; D009853:Omeprazole / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology; D003245:Consensus Statements as Topic
D000658:Amoxicillin; D000897:Anti-Ulcer Agents; D001729:Bismuth; D017291:Clarithromycin; D009853:Omeprazole